Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Researchers have developed RNA therapeutics, called micelles, that can delivery chemotherapeutic drugs to metastasized tumors in mouse models.

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

When cancer-driving proteins resist various treatments, Northwestern University scientists have uncovered a new solution. Don ...

A growing body of research has examined the IRA’s implications for pharmaceutical innovation. Much of this literature has focused on the potential impact on the number of new drug launches, 5, 6 but ...

FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast ...

CEOCFO interviews NanOlogy, LLC CEO David J. Arthur on Solving Toxicity & Bioavailability Problems when Treating ...

While Vir Biotech is best known for its work on infectious diseases, its developing cancer pipeline has delivered a partnership with Astellas that could be worth around $1.4 billion.

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...